Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
7.05
+0.01 (0.14%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Monte Rosa Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Cash & Equivalents
128.155.87346.0742.869.25
Short-Term Investments
104.31207.91000
Cash & Cash Equivalents
232.41263.79346.0742.869.25
Cash Growth
-11.89%-23.78%707.39%363.63%-
Receivables
0.517.66000
Other Current Assets
3.294.442.60.730.51
Total Current Assets
236.21275.89348.6743.599.76
Property, Plant & Equipment
62.6161.9112.334.621.34
Long-Term Investments
4.584.325.3400
Other Long-Term Assets
0.350.2801.160
Total Long-Term Assets
67.5466.517.665.791.34
Total Assets
303.76342.39366.3349.3811.09
Accounts Payable
11.157.866.567.073.2
Deferred Revenue
500000
Current Debt
3.163.13000.75
Other Current Liabilities
-17.7214.5810.0822.210.35
Total Current Liabilities
46.5925.5716.6429.284.29
Long-Term Debt
42.8843.87000
Other Long-Term Liabilities
35.041.532.181.070
Total Long-Term Liabilities
77.9145.412.181.070
Total Liabilities
124.5170.9818.8130.344.29
Total Debt
46.0447000.75
Debt Growth
-2.05%----
Retained Earnings
-365.89-230.54-122.04-48.08-12.2
Comprehensive Income
-2.72-1.75-2.02-1.060
Shareholders' Equity
179.25271.41347.52-48.73-12.15
Net Cash / Debt
186.37216.79346.0742.868.5
Net Cash / Debt Growth
-14.03%-37.36%707.39%404.57%-
Net Cash Per Share
3.634.5913.8428.261.70
Working Capital
189.62250.32332.0314.325.47
Book Value Per Share
3.495.7513.90-32.12-2.43
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).